Nativa, the Russian pharmaceutical company founded in 2010, recently announced a strategic agreement concerning cooperation in the manufacture of dispensing systems for respiratory disease treatment with Vari, a wholly-owned subsidiary of Lindal Group and one of the leading makers of valves and actuators for pharmaceutical aerosol systems.
Such cooperation includes metered dose inhalers, which require the highest levels of technical and manufacturing expertise. These solutions use carefully engineered valves made to handle active ingredients and optimize delivery of low doses of medication directly inside the bronchial tree.
Both Vari and Nativa anticipate further growth of their business relationship. "Lindal is pleased to have this opportunity to broaden its relationship with Nativa," said Phil Lever, Group Sales Director for the pharmaceutical company.
According to Alexander Malin, CEO of Nativa, "Our company values are focused on our own R&D development and low-batch production, as well as the involvement of the world's leaders in related technology.
"One of the significant results of the long-term partnership between Nativa and the European leader Vari-Lindal Group was the strategic agreement for technology transfer of drug manufacturing for respiratory disease treatment in the form of metered aerosol," he added. "This joint project will allow us to market high-demand drugs for patients and citizens of the Russian Federation, to [adapt] the European technology to the Russian environment, as well as to create favorable conditions for release of the series of drugs based on our process."
Vari, located in northern Italy, has manufactured 20-mm metering valves for a range of pharmaceutical applications for more than 30 years, and supplies pharmaceutical companies around the world.
The Lindal Group, headquartered in Hamburg, Germany, is a global manufacturer of valves, actuators and spray caps for aerosol products used in pharmaceutical, cosmetic and food applications.